First News

The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the WHO, there were 96,012,792 confirmed cases of COVID-19, including 2,075,870 deaths (as of January 22, 2021). Due to the pandemic, companies have scaled up R&D efforts to develop a vaccine and drugs against the SARS-CoV-2 virus. Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. Due to the increase in research activities, both the availability of funding for research and the demand for and manufacturing of cell-based assay products are expected to grow. The players operating in the market are altering their long-term and short-term growth strategies by tapping into opportunities prevalent in the research market by developing innovative products to combat the pandemic. The increased demand for research on COVID...

Growing funding and investments in R&D, the increasing prevalence of chronic disorders, increase in drug discovery activities, and the advantages of cell-based assays over alternative technologies are expected to drive the growth of this market. The market is classified into drug discovery, basic research, ADME studies, predictive toxicology and other applications. The drug manufacturers are mostly confined to using cell-based assays during the drug development process, this drives the drug discovery applications segment and helps the segment hold the largest share of the cell-based assays market in 2017. The global market is segmented by product, application, end user, and region. By product, the global market is segmented into consumables, instruments, service and software. The consumables segment is expected to lead the global  cell based assays market  in 2017. The rising prevalence of chronic disorders and technical innovations in the field are key growth factors of t...